Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2014 / Cilt: 40 - Sayı: 4

Mesane kanseri için mevcut ve geliştirilmekte olan moleküler belirteçler nelerdir? Gelecekte de faydalı olacaklarını nasıl kanıtlayabilirler?

What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?

Pages
228–232
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Urinary NMP22 has an overall sensitivity and specifcity for detecting bladder cancer of 49% and 87%, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Urothelial carcinoma is the 9 th most common cancer worldwide.
📊
Key Findings & Data:However, two-thirds of non-invasive bladder cancers will eventually recur with a 25% risk of progression to muscle-invasive bladder cancer.
💡
Conclusion & Impact:Urinary NMP22 has an overall sensitivity and specifcity for detecting bladder cancer of 49% and 87%, respectively.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Urothelial carcinoma is the 9 th most common cancer worldwide. Most urothelial tumors are non-muscle invasive on presentation. However, two-thirds of non-invasive bladder cancers will eventually recur with a 25% risk of progression to muscle-invasive bladder cancer. Tumor stage, histological grade and pathological invasion of blood vessels and lymphatic tissue are the main indicators for urothelial cancer prognosis. The gold standard for diagnosing bladder cancer is conventional white-light cystoscopy and biopsy. Urine cytology is a highly specifc, sensitive test for high-grade tumors or carcinoma in situ (CIS). Urinary NMP22 has an overall sensitivity and specifcity for detecting bladder cancer of 49% and 87%, respectively. However, there are falsepositive results in the presence of urinary tract infection or hematuria. The detection of specifc gene mutations related to urothelial cancers has been studied and employed to reproduce markers helpful for diagnosis. According to current studies, molecular markers can be used to predict tumor recurrence. From a prognostic point of view, new molecular markers have yet to be established as reliable indicators of tumor aggressiveness. We aimed to review the molecular markers with possible prognostic signifcance that have been discussed in the literature. This review examined the literature for various molecular markers under development for bladder cancer in an attempt to optimize patient care and reduce the costs of treating these patients.

Özet

Mesane kanseri; dünyada en yaygın 9. kanserdir. Ürotelyal tümörlerin çoğu başvuru esnasında kasa invaze olmamıştır. Bununla birlikte, non-invaziv mesane kanserlerinin üçte ikisinde rekürrens gelişecek ve %25 kasa invaze mesane kanserine progresyon göstereceklerdir. Ürotelyal kanser prognozu için temel göstergeler; tümör evresi, histolojik grade, kan damarlarına ve lenfatik dokuya patolojik invazyondur. Mesane kanserinin teşhisinde altın standart yöntem, geleneksel sistoskopi ve biyopsidir. İdrar sitolojisi, yüksek grade’li tümörler veya karsinoma in situ (CIS) için oldukça sensitif ve spesifik bir testtir. Üriner Nükleer Matriks Protein-22’nin (NMP-22) mesane kanserini saptamada sensitivitesi %49, spesifitesi ise %87’dir. Ancak, üriner enfeksiyon ya da hematüri durumunda, yanlış-pozitif sonuçlar olabilmektedir. Son yıllarda, ürotelyal kanserle ilişkili spesifik gen mutasyonlarının saptanmasına çalışılmakta ve bu gen mutasyonları, teşhis için yardımcı olabilecek belirteçlerin üretiminde kullanılmaktadır. Son zamanlarda yapılan araştırmalara göre, moleküler belirteçler tümör rekürrensinin önceden tahmininde kullanılabilmektedir. Yine de, prognostik açıdan, yeni moleküller tümör agresifliğinin güvenilir göstergesi olarak henüz tam kabul görmemişlerdir. Biz bu çalışmamızda, literatürde tartışılan muhtemel prognostik önemi olan moleküler belirteçleri gözden geçirmeyi amaçladık. Bu derleme, mesane kanserli hastaların tedavilerini daha uygun hale getirip bu hastaların tedavi masraflarını azaltan, mesane kanserine yönelik çeşitli moleküler belirteçleri inceleyen literatürü içermektedir.

🔖

Cite This Article

ABDULMAJED, M. I., SANCAK, E. B., REŞORLU, B., AL-CHALABY, G. Z. (2014). Mesane kanseri için mevcut ve geliştirilmekte olan moleküler belirteçler nelerdir? Gelecekte de faydalı olacaklarını nasıl kanıtlayabilirler?. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 40 - Sayı: 4, 228–232. https://ajindex.com/articles/327972

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008
  2. [CrossRef] 2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008
  3. [CrossRef] 3. Lopez-Beltran A. Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl 2008
  4. [CrossRef] 4. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh Urology. USA: Saunders
  5. p.2316-23. 5. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998
  6. [CrossRef] 6. Millan-Rodriguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodríguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000
  7. [CrossRef] 7. Wolf H, Kakizoe T, Smith PH, Brosman SA, Okajima E, Rübben H, et al. Bladder tumors. Treated natural history. Prog Clin Biol Res 1986
  8. Leissner J, Koeppen C, Wolf HK. Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. The J Urol 2003
  9. [CrossRef] 9. Kaba M, Pirincci N, Benli E, Gecit I, Gunes M, Yuksel MB, et al. Dickkopf-1 levels in Turkish patients with bladder cancer and its association with clinicopathological features. Asian Pac J Cancer Prev 2014
  10. [CrossRef] 10. Pirinççi N, Geçit I, Güneş M, Yüksel MB, Kaba M, Tanık S, et al. Serum adenosine deaminase, catalase and carbonic anhydrase activities in patients with bladder cancer. Clinics (Sao Paulo) 2012
  11. [CrossRef] 11. Tiguert R, Lessard A, So A, Fradet Y. Prognostic markers in muscle invasive bladder cancer. World J Urol 2002
  12. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al. A phase III, multicenter comparison of hexaminolevu - linate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007
  13. [CrossRef] 13. Geavlete B, Jecu M, Multescu R, Geavlete P. Narrow-band imaging cys- toscopy in non-muscle-invasive bladder cancer: a prospective comparison to the standard approach. Ther Adv Urol 2012
  14. [CrossRef] 14. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, et al.